Lyra Therapeutics Inc (NASDAQ:LYRA) — Market Cap & Net Worth
Market Cap & Net Worth: Lyra Therapeutics Inc (LYRA)
Lyra Therapeutics Inc (NASDAQ:LYRA) has a market capitalization of $1.15 Million ($1.15 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30421 globally and #6103 in its home market, demonstrating a -26.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lyra Therapeutics Inc's stock price $0.65 by its total outstanding shares 1774882 (1.77 Million). Review LYRA current and long-term liabilities to assess the company's total debt and financial obligations.
Lyra Therapeutics Inc Market Cap History: 2020 to 2026
Lyra Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows change from $20.23 Million to $1.15 Million (-42.13% CAGR).
Index Memberships
Lyra Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.00% | #903 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #2867 of 3165 |
Weight: Lyra Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lyra Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lyra Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.74x
Lyra Therapeutics Inc's market cap is 13.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $7.74 Million | $285.00K | -$42.41 Million | 27.15x | N/A |
| 2022 | $5.57 Million | $1.36 Million | -$55.28 Million | 4.09x | N/A |
| 2023 | $9.30 Million | $1.56 Million | -$62.68 Million | 5.97x | N/A |
| 2024 | $366.34K | $1.53 Million | -$93.44 Million | 0.24x | N/A |
| 2025 | $5.47 Million | $398.00K | -$28.92 Million | 13.74x | N/A |
Competitor Companies of LYRA by Market Capitalization
Companies near Lyra Therapeutics Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Lyra Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Lyra Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Lyra Therapeutics Inc's market cap moved from $20.23 Million to $ 1.15 Million, with a yearly change of -42.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.15 Million | -78.90% |
| 2025 | $5.47 Million | +1392.25% |
| 2024 | $366.34K | -96.06% |
| 2023 | $9.30 Million | +66.88% |
| 2022 | $5.57 Million | -27.98% |
| 2021 | $7.74 Million | -61.75% |
| 2020 | $20.23 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Lyra Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.15 Million USD |
| MoneyControl | $1.15 Million USD |
| MarketWatch | $1.15 Million USD |
| marketcap.company | $1.15 Million USD |
| Reuters | $1.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-infla… Read more